Vaccination for preventing postherpetic neuralgia

摘要: Background Herpes zoster virus vaccine was recommended for the prevention of herpes and its sequelae by Advisory Committee on Immunization Practices (ACIP) in 2006. To date efficacy safety vaccination preventing most common complication zoster, postherpetic neuralgia, has not been systematically reviewed. Objectives To assess the efficacy and safety of vaccination neuralgia. Search methods We searched Cochrane Neuromuscular Disease Group Specialized Register (10 January 2011), Central Controlled Trials (CENTRAL) Issue 4, 2010 Library), MEDLINE (January 1966 to December 2010), EMBASE 1980 LILACS 1982 Chinese Biomedical Retrieval System 1978 2010). We also checked references published studies identify additional trials. Selection criteria We included all randomised controlled trials comparing varicella with placebo, no or another intervention, irrespective publication status language. Data collection analysis Two authors independently assessed trial quality, then extracted analysed data from trials which met inclusion criteria. collected adverse effects information trials. Main results One trial, involved 38,546 subjects compared our This study high quality. However, participants were aged 60 years more them white, may mean that findings are applicable populations. The effective decreasing incidence but there evidence it had reducing neuralgia beyond effect zoster. Adverse events at injection site among recipients than placebo recipients, they mild resolved a few days. Serious rare. Authors' conclusions There is insufficient direct specialised prove although be efficacious safe thus reduce adults older.